GLP-1 RA use is associated with a significant loss of lean body mass, including skeletal muscle mass
2 Wegovy is available on the NHS for adults with: A BMI of 35 or higher (32.5 or higher for people from South Asian, Chinese, other Asian, Middle Eastern, Black African, or African-Caribbean backgrounds) At least one weight-related condition (type 2 diabetes, hypertension, cardiovascular disease, obstructive sleep apnoea, or dyslipidaemia) Referral to and engagement with a specialist weight management service (Tier 3) NICE caps NHS treatment with Wegovy at two years
:
Colitis aggravated by Mrgprb2 knockout is associated with altered immune response, intestinal barrier function and gut microbiota
Following the treatment, the body takes over with its natural waste removal mechanisms
Suitable for vegans and vegetarians